Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan

Business Wire February 1, 2016

Philogen Announces Exercise of Options Within the License Agreement With Pfizer Inc. for the Development and Potential Commercialization of Multiple Antibody Drug Conjugates (ADCs) and Targeted Technologies

PR Newswire January 21, 2016

ViiV Healthcare & the Los Angeles Department of Health Services Announce New Fellowship Program to Address a Growing Shortage of Primary Care HIV Specialists

PR Newswire January 19, 2016

Write A Prescription For This Healthcare ETF

Benzinga.com  January 15, 2016

Pfizer Acquires Treerly and Its Family of Products from Sirio Pharma

Business Wire January 13, 2016

California Institute for Biomedical Research (Calibr) enters worldwide strategic collaboration with Pfizer Inc.

PR Newswire January 13, 2016

ChapStick® Announces Actress Rachel Bilson as New Brand Spokesperson

Business Wire January 11, 2016

HemoShear Therapeutics Announces Next Stage of Safety Collaboration with Pfizer Inc.

PR Newswire January 11, 2016

Pfizer Expands R&D Equity Investment Strategy to Access Early-Stage Scientific Innovations

Business Wire January 8, 2016

Pfizer Enters into Translational Research Collaboration with Adaptive Biotechnologies to Help Advance Novel Immuno-Oncology Solutions

Business Wire January 8, 2016

ViiV Healthcare to Progress Collaboration with Janssen to Develop the First Long-acting, Two Drug Injectable Regimen for Treatment of HIV-1 Infection

PR Newswire January 7, 2016

Pfizer Invites Public to Listen to Webcast of Pfizer and Allergan Discussion at 34th Annual J.P. Morgan Healthcare Conference

Business Wire January 5, 2016

Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer

Business Wire January 4, 2016

The Two Best Sector SPDR ETFs For January

Benzinga.com  January 2, 2016

2015 saw $5 trillion in global acquisition deals: Here's some of the biggies

Canadian Press December 30, 2015

Peering Through The Fog To Find The Best Sectors Into Year End

Benzinga.com  December 23, 2015

Pfizer Invites Public To View And Listen To Webcast Of February 2 Conference Call With Analysts

Business Wire December 22, 2015

Merck KGaA, Darmstadt, Germany and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab

Business Wire December 22, 2015

Pfizer Reports Top Line Results from a Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation in Pediatric Patients with Major Depressive Disorder

Business Wire December 21, 2015

Pfizer Declares First-Quarter 2016 Dividend

Business Wire December 14, 2015